Analysis of the inhibition mechanism of cholesterol transporter NPC1L1 by ezetimibe
Project/Area Number |
25860132
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Medical pharmacy
|
Research Institution | Fukuyama University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | コレステロール / NPC1L1 / エゼチミブ |
Outline of Final Research Achievements |
NPC1L1 is known as cholesterol transporter. Ezetimibe inihibits NPC1L1 and is used as cholesterol lowering drug. We analyzed the effects of NPC1L1 mutants. Although V55L mutant showed no effect on NPC1L1 function, we found that extracellular portion of NPC1L1 plays an important role on its function. Furthermore, we analyzed the substrate recognition mechanism of NPC1L1. We showed that NPC1L1 recognizes alpha-tocopherol as well as cholesterol.
|
Report
(3 results)
Research Products
(5 results)